ORIGINAL RESEARCH article
Front. Neurol.
Sec. Endovascular and Interventional Neurology
This article is part of the Research TopicResearch on the Correlative Mechanisms and Clinical Exploration of Headache and Cerebrovascular DiseasesView all 12 articles
Drug-coated balloon versus conventional balloon for stent angioplasty in symptomatic intracranial atherosclerotic stenosis
Provisionally accepted
Lili Sun
Chao Chen
Wei Zhao
Yun Song
Meimei ZhengHao Yin
Jun ZhangYao Meng
Wei Wang
Weili Li
Chenlu Zhu
Ju Han*- Shandong Provincial Qianfoshan Hospital, Jinan, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Abstract Background Due to limited evidence on the optimal strategy for intracranial atherosclerotic stenosis (ICAS), further evidence on the safety and efficacy of drug-coated balloon (DCB) predilation stent angioplasty was aimed to be provided. Methods Consecutive patients with symptomatic medically refractory ICAS from January 2016 to November 2022 who underwent balloon predilation stent angioplasty were retrospectively analyzed and dichotomized by whether DCB or conventional balloon (CB) was used. The efficacy and safety endpoints were compared by propensity score matching. Results A total of 95 patients in the DCB group and 100 patients in the CB group were selected. Of these, 134 patients were matched. The in-stent restenosis (ISR) incidence (1.5% vs 16.4%, P = 0.006) and the median (IQR) stenosis degree at follow-up in the DCB group were significantly lower than those in the CB group (0(0) vs 0(0), P = 0.031). The primary safety endpoint within 30 days and secondary safety endpoints from 31 days to 1 year were not statistically different between the two groups. Conclusions Compared with CB predilation stent angioplasty, DCB predilation stent angioplasty effectively reduced the degree of restenosis and the risk of ISR, but had no advantage in terms of symptomatic restenosis risk currently. However, these findings should be interpreted cautiously because of the aforementioned limitations, and prospective multicenter randomized studies with larger patient number will be required to establish the efficacy and safety of DCB.”
Keywords: Drug-coated balloon, Intracranial atherosclerotic stenosis, in- stent restenosis, Stent angioplasty, Stroke
Received: 17 Sep 2025; Accepted: 09 Dec 2025.
Copyright: © 2025 Sun, Chen, Zhao, Song, Zheng, Yin, Zhang, Meng, Wang, Li, Zhu and Han. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Ju Han
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.